Swiss Scientists Explore Methylene Blue as a Potential Treatment for COVID-19

Medical-News: The relentless global pandemic has pushed scientists and researchers to explore both new and existing drugs to treat COVID-19. One such drug is Methylene Blue (MB), historically used in various medical treatments, including malaria and blood sterilization. In a recent clinical trial, researchers from the Fondazione Epatocentro Ticino, Switzerland, and the University of Applied Sciences and Arts of Southern Switzerland conducted a study to evaluate the effectiveness of Methylene Blue against SARS-CoV-2 infection. This Medical News report will cover the study's key findings, offering insights into whether Methylene Blue holds promise for treating early-stage COVID-19 patients.

 Swiss Scientists Explore Methylene Blue as a Potential Treatment for COVID-19

Understanding Methylene Blue and Its Potential
Methylene Blue is a synthetic dye with known medicinal applications for over a century. In previous studies, Methylene Blue has shown antiviral properties and has been used in combination with UV light to sterilize blood, particularly against viruses like SARS-CoV. A recent observational study from France involving over 2,000 cancer patients who took Methylene Blue daily noted that none of them developed flu-like symptoms during the first wave of the pandemic. This observation prompted the researchers to explore Methylene Blue’s potential as a prophylactic or therapeutic agent for COVID-19.
 
Given these promising hints, the Swiss research team designed a phase 2, randomized, placebo-controlled trial to investigate the drug’s effectiveness against SARS-CoV-2.
 
Study Design: How the Trial Was Conducted
The clinical trial was a single-blind, placebo-controlled study aimed at examining Methylene Blue’s efficacy in reducing viral load in COVID-19 patients. Eligible participants included adults with mild COVID-19 infections who could be managed at home. Patients with a confirmed positive test for SARS-CoV-2 were administered either Methylene Blue or a placebo.
 
The trial’s regimen for the Methylene Blue group involved a loading dose of 200 mg in the morning and 100 mg in the evening on the first day, followed by 100 mg twice daily for four additional days. The placebo group received capsules that mimicked the Methylene Blue regimen without any active ingredients. Patients in both groups were closely monitored, with regular check-ups to assess their viral load, symptoms, and any potential side effects.
 
Evaluating the Results: Did Methylene Blue Show Promise?
In this trial, 29 patients were initially recruited, and after exclusions, 19 were analyzed for efficacy - 11 in the Methylene Blue group and 8 in the placebo group. The trial aimed to assess viral load reduction, which was measured over a 21-day period. This was achieved by calculating the area under the curve (AUC) of the viral load, providing a snapshot of each group’s overall infection status.
 
Interestingly, both the Methylene Blue and placebo groups showed a r eduction in viral load over time, with 10 out of 11 patients in the MB group becoming virus-free by day 12, compared to 6 out of 8 in the placebo group. By day 21, all patients had cleared the virus. However, no statistically significant difference was found between the groups, meaning that Methylene Blue did not exhibit superior efficacy over the placebo in terms of faster viral clearance.
 
The researchers also analyzed secondary endpoints, such as the rate of patients achieving at least a 2-log reduction in viral load by day 3. Only one patient in the placebo group met this criterion, while none in the MB group did. Despite these findings, Methylene Blue demonstrated a comparable safety profile, as no serious adverse events were reported in either group.
 
Exploring Safety and Side Effects of Methylene Blue
Safety is a critical consideration in clinical trials, especially for a drug that could be administered to large populations. This study carefully tracked any adverse events experienced by participants. Side effects in the MB group were generally mild and included gastrointestinal discomfort, dysuria, and a transient increase in liver enzymes - consistent with known side effects of MB. Importantly, no serious adverse effects were recorded, indicating that Methylene Blue is well-tolerated in patients with mild COVID-19.
 
Limitations of the Study and Areas for Further Research
While this study provides valuable insights, it is important to acknowledge its limitations. One major constraint was the limited sample size. Although 29 patients were recruited, only 19 completed the trial, and the small group sizes make it difficult to generalize the findings. Additionally, seven patients had already cleared the virus between the initial diagnosis and the first viral load measurement, further reducing the number of participants for analysis.
 
The changing nature of the COVID-19 pandemic also affected the trial. The majority of participants were infected with the Omicron variant, which is typically less severe in symptoms than earlier strains. This change in disease severity could impact how Methylene Blue affects virus progression. Lastly, due to logistical challenges and decreasing COVID-19 case numbers, the trial was stopped after an interim analysis, meaning that a larger-scale study would be needed to draw more conclusive results.
 
Conclusion: What Does This Mean for Methylene Blue as a COVID-19 Treatment?
While Methylene Blue has demonstrated antiviral properties in laboratory settings, this clinical trial did not establish it as a significantly more effective treatment for SARS-CoV-2 compared to a placebo in a real-world setting. However, the safety and tolerability of Methylene Blue were confirmed, and the drug did not produce serious adverse effects, making it a viable option for further investigation.
 
The results suggest that although Methylene Blue may not drastically alter the course of SARS-CoV-2 infection, it could have benefits in specific contexts, such as shortening recovery time or serving as an adjunct treatment. Larger studies with more participants and different variants of the virus may yield additional insights. Ultimately, while Methylene Blue did not demonstrate overwhelming efficacy in this study, its role in COVID-19 treatment cannot be dismissed without further research.
 
The study findings were published in the peer-reviewed journal: Scientia Pharmaceutica.
https://www.mdpi.com/2218-0532/92/4/56
 
For the latest COVID-19 News, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/methylene-blue-shows-promise-in-preventing-vision-loss-in-glaucoma-patients
 
https://www.thailandmedical.news/news/sars-cov-2-spike-proteins-causes-mitochondrial-dysfunction-and-exhibits-warburg-effect,-leading-to-redox-shift-and-cellular-anabolism